北京九强生物技术股份有限公司 相关债券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【439】号 01 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客 观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未 ...

6月12日，利德曼今日收盘5.22元，上涨1.36%，最新市净率1.71，创79天以来新低，总市值28.40亿元。 截至2025年一季报，共有3家机构持仓利德曼，其中其他2家、基金1家，合计持股数26307.52万股，持 股市值12.39亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)14利德曼-38.56-37.811.7128.40亿行业平均 50.9948.894.72108.92亿行业中值37.1839.082.4849.75亿1天益医疗-1820.70-3118.651.9423.20亿2澳华内 镜-677.24339.675.4371.37亿3诺唯赞-427.09-505.142.3491.40亿4爱朋医疗-422.29320.825.0934.65亿5博晖 创新-340.19539.833.6349.91亿6奥精医疗-157.17-230.362.0729.17亿7硕世生物-143.29-2093.881.2841.91亿 8睿昂基因-107.20-88.011.5213.87亿9康泰医学-86.81-73.343.1057.14亿10中红医疗-73.07-58.280.9250. ...

5月27日，利德曼今日收盘4.98元，上涨1.84%，最新市净率1.63，总市值27.09亿元。 来源：金融界 资金流向方面，5月27日，利德曼主力资金净流出349.78万元，近5日总体呈流出状态，5日共流出775.43 万元。 最新一期业绩显示，2025年一季报，公司实现营业收入7890.87万元，同比-16.61%；净利润-1251725.54 元，同比53.73%，销售毛利率53.56%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)14利德曼-36.79-36.071.6327.09亿行业平均 49.1147.374.60105.87亿行业中值35.8936.632.3948.39亿1天益医疗-1748.54-2995.051.8722.28亿2澳华内 镜-629.96315.965.0566.39亿3诺唯赞-396.80-469.312.1884.92亿4爱朋医疗-348.40264.684.2028.59亿5博晖 创新-323.49513.323.4547.46亿6硕世生物-133.76-1954.591.2039.13亿7奥精医疗-130.30-190.981.7224.18亿 8睿昂 ...

5月20日，利德曼今日收盘5.04元，上涨1.61%，最新市净率1.65，创40天以来新低，总市值27.42亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入7890.87万元，同比-16.61%；净利润-1251725.54 元，同比53.73%，销售毛利率53.56%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)14利德曼-37.23-36.511.6527.42亿行业平均 49.5147.734.57106.36亿行业中值36.1737.202.5148.58亿1天益医疗-1784.15-3056.061.9022.74亿2澳华内 镜-619.74310.834.9665.31亿3诺唯赞-415.76-491.732.2888.97亿4爱朋医疗-370.37281.374.4630.39亿5博晖 创新-330.72524.813.5348.52亿6硕世生物-137.27-2005.841.2340.15亿7奥精医疗-130.15-190.761.7224.15亿 8睿昂基因-105.86-86.911.5013.70亿9康泰医学-86.99-73.503.1057.26亿10中红医 ...

Group 1 - The core viewpoint of the news is that Lidman Biochemical Co., Ltd. is experiencing a decline in revenue and profit, with a significant drop in stock price and market performance [1] - As of April 29, Lidman closed at 4.6 yuan, up 2.00%, with a latest price-to-book ratio of 1.51, marking a new low in 18 days, and a total market value of 2.502 billion yuan [1] - In terms of capital flow, on April 29, Lidman saw a net outflow of 2.7495 million yuan, with a total outflow of 1.6919 million yuan over the past five days [1] Group 2 - The main business of Lidman includes research, production, sales, and service of in vitro diagnostic reagents, diagnostic instruments, and biochemical raw materials [1] - The company's key products consist of biochemical diagnostic reagents, immunodiagnostic reagents, and automated chemiluminescence immunoassay analyzers [1] - Recent performance data shows that in Q1 2025, the company achieved operating revenue of 78.9087 million yuan, a year-on-year decrease of 16.61%, and a net profit of -1,251,725.54 yuan, a year-on-year decline of 53.73%, with a gross profit margin of 53.56% [1] Group 3 - Lidman has received several accolades, including "National High-tech Enterprise," "Zhongguancun High-tech Enterprise," and recognition as a leading enterprise in the "G20 Project" for the Beijing biopharmaceutical industry [1] - The company was also recognized as a "Benchmark Enterprise in Intelligent Manufacturing" in Beijing for 2018 and received certification for "Digital Workshop" in 2022 [1] Group 4 - In comparison to industry averages, Lidman's PE (TTM) is -33.98, and its price-to-book ratio is 1.51, while the industry average PE is 47.74 and the average price-to-book ratio is 4.40 [2] - The industry median PE is 36.15, with a median price-to-book ratio of 2.28, indicating that Lidman is underperforming relative to its peers [2]